Gerometabolites: The pseudohypoxic aging side of cancer oncometabolites

Oncometabolites are defined as small-molecule components (or enantiomers) of normal metabolism whose accumulation causes signaling dysregulation to establish a milieu that initiates carcinogenesis. In a similar manner, we propose the term “gerometabolites” to refer to small-molecule components of normal metabolism whose depletion causes signaling dysregulation to establish a milieu that drives aging. In an investigation of the pathogenic activities of the currently recognized oncometabolites R(-)-2-hydroxyglutarate (2-HG), fumarate, and succinate, which accumulate due to mutations in isocitrate dehydrogenases (IDH), fumarate hydratase (FH), and succinate dehydrogenase (SDH), respectively, we illustrate the fact that metabolic pseudohypoxia, the accumulation of hypoxia-inducible factor (HIFα) under normoxic conditions, and the subsequent Warburg-like reprogramming that shifts glucose metabolism from the oxidative pathway to aerobic glycolysis are the same mechanisms through which the decline of the “gerometabolite” nicotinamide adenine dinucleotide (NAD)+ reversibly disrupts nuclear–mitochondrial communication and contributes to the decline in mitochondrial function with age. From an evolutionary perspective, it is reasonable to view NAD+-driven mitochondrial homeostasis as a conserved response to changes in energy supplies and oxygen levels. Similarly, the natural ability of 2-HG to significantly alter epigenetics might reflect an evolutionarily ancient role of certain metabolites to signal for elevated glutamine/glutamate metabolism and/or oxygen deficiency. However, when chronically altered, these responses become conserved causes of aging and cancer. Because HIFα-driven pseudohypoxia might drive the overproduction of 2-HG, the intriguing possibility exists that the decline of gerometabolites such as NAD+ could promote the chronic accumulation of oncometabolites in normal cells during aging. If the sole activation of a Warburg-like metabolic reprogramming in normal tissues might be able to significantly increase the endogenous production of bona fide etiological determinants in cancer, such as oncometabolites, this undesirable trade-off between mitochondrial dysfunction and activation of oncometabolites production might then pave the way for the epigenetic initiation of carcinogenesis in a strictly metabolic-dependent manner. Perhaps it is time to definitely adopt the view that aging and aging diseases including cancer are governed by a pivotal regulatory role of metabolic reprogramming in cell fate decisions.

[1]  Y. Makino,et al.  Tubular Injury in a Rat Model of Type 2 Diabetes Is Prevented by Metformin , 2011, Diabetes.

[2]  Jim Watson,et al.  Oxidants, antioxidants and the current incurability of metastatic cancers , 2013, Open Biology.

[3]  R. Iglesias-Bartolome,et al.  Exploiting the mTOR paradox for disease prevention , 2012, Oncotarget.

[4]  D. Sabatini,et al.  Cancer cell metabolism: one hallmark, many faces. , 2012, Cancer discovery.

[5]  David A Sinclair,et al.  Geroncogenesis: metabolic changes during aging as a driver of tumorigenesis. , 2014, Cancer cell.

[6]  Kathryn A. O’Donnell,et al.  Myc Stimulates Nuclearly Encoded Mitochondrial Genes and Mitochondrial Biogenesis , 2005, Molecular and Cellular Biology.

[7]  Eyal Gottlieb,et al.  Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. , 2005, Cancer cell.

[8]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[9]  G. Evan,et al.  Modelling Myc inhibition as a cancer therapy , 2008, Nature.

[10]  R. Deberardinis,et al.  Genetically-defined metabolic reprogramming in cancer , 2012, Trends in Endocrinology & Metabolism.

[11]  P. Rustin,et al.  The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. , 2001, American journal of human genetics.

[12]  S. Baylin,et al.  5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft , 2013, Oncotarget.

[13]  R. Verhaak,et al.  Transformation by the R Enantiomer of 2-Hydroxyglutarate Linked to EglN Activation , 2012, Nature.

[14]  A. Gudkov,et al.  Hypoxia suppresses conversion from proliferative arrest to cellular senescence , 2012, Proceedings of the National Academy of Sciences.

[15]  A. Menssen,et al.  The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop , 2011, Proceedings of the National Academy of Sciences.

[16]  Bin Wang,et al.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. , 2011, Cancer cell.

[17]  Russell G. Jones,et al.  Hypoxia-induced energy stress regulates mRNA translation and cell growth. , 2006, Molecular cell.

[18]  Johan Auwerx,et al.  Sirtuins as regulators of metabolism and healthspan , 2012, Nature Reviews Molecular Cell Biology.

[19]  G. Evan,et al.  Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. , 2013, Genes & development.

[20]  Chi V. Dang,et al.  The interplay between MYC and HIF in cancer , 2008, Nature Reviews Cancer.

[21]  M. Ohh,et al.  The updated biology of hypoxia‐inducible factor , 2012, The EMBO journal.

[22]  Fang Wang,et al.  An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells , 2013, Science.

[23]  J. Auwerx,et al.  Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle. , 2010, Cell metabolism.

[24]  M. Blagosklonny,et al.  The purpose of the HIF-1/PHD feedback loop: To limit mTOR-induced HIF-1α , 2011, Cell cycle.

[25]  P. Pollard,et al.  Succinate: a new epigenetic hacker. , 2013, Cancer cell.

[26]  L. Penn,et al.  Reflecting on 25 years with MYC , 2008, Nature Reviews Cancer.

[27]  M. Blagosklonny.  Once again on rapamycin-induced insulin resistance and longevity: despite of or owing to , 2012, Aging.

[28]  N. Lago,et al.  High fat diet-induced liver steatosis promotes an increase in liver mitochondrial biogenesis in response to hypoxia , 2010, Journal of cellular and molecular medicine.

[29]  E. Mercken,et al.  Declining NAD+ Induces a Pseudohypoxic State Disrupting Nuclear-Mitochondrial Communication during Aging , 2013, Cell.

[30]  V. Haase.  The VHL tumor suppressor: master regulator of HIF. , 2009, Current pharmaceutical design.

[31]  Matthew G. Vander Heiden,et al.  Metabolic targets for cancer therapy , 2013, Nature Reviews Drug Discovery.

[32]  C. Treins,et al.  AMPK activation inhibits the expression of HIF-1α induced by insulin and IGF-1 , 2006 .

[33]  M. Blagosklonny.  NCI's provocative questions on cancer: some answers to ignite discussion , 2011, Oncotarget.

[34]  J. Stebbing,et al.  IDH mutations in tumorigenesis and their potential role as novel therapeutic targets. , 2013, Future oncology.

[35]  A. Menssen,et al.  c-MYC and SIRT1 locked in a vicious cycle , 2012, Oncotarget.

[36]  E. Cuyás,et al.  The Warburg effect version 2.0: Metabolic reprogramming of cancer stem cells , 2013, Cell cycle.

[37]  Z. Lou,et al.  A c-Myc–SIRT1 feedback loop regulates cell growth and transformation , 2009, The Journal of cell biology.

[38]  D. Sinclair,et al.  Manipulation of a nuclear NAD+ salvage pathway delays aging without altering steady-state NAD+ levels. , 2013, The Journal of Biological Chemistry.

[39]  W. D. Martin,et al.  Mitochondrial genome instability and ROS enhance intestinal tumorigenesis in APC(Min/+) mice. , 2012, The American journal of pathology.

[40]  P. Bénit,et al.  Mitochondrial succinate is instrumental for HIF1alpha nuclear translocation in SDHA-mutant fibroblasts under normoxic conditions. , 2005, Human molecular genetics.

[41]  Fang Wang,et al.  Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation , 2013, Science.

[42]  Stella Pelengaris,et al.  c-MYC: more than just a matter of life and death , 2002, Nature Reviews Cancer.

[43]  F. Agani,et al.  Oxygen-independent regulation of HIF-1: novel involvement of PI3K/AKT/mTOR pathway in cancer. , 2013, Current cancer drug targets.

[44]  E. Gottlieb,et al.  Prolyl hydroxylases as regulators of cell metabolism. , 2009, Biochemical Society transactions.

[45]  T. Soga,et al.  Rare insights into cancer biology , 2014, Oncogene.

[46]  L. Soucek,et al.  Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis. , 2002, Cancer research.

[47]  S. McMahon,et al.  Analysis of genomic targets reveals complex functions of MYC , 2004, Nature Reviews Cancer.

[48]  Angeliki Chalkiadaki,et al.  Sirtuins mediate mammalian metabolic responses to nutrient availability , 2012, Nature Reviews Endocrinology.

[49]  N. Oldham,et al.  Structural and Mechanistic Studies on the Inhibition of the Hypoxia-inducible Transcription Factor Hydroxylases by Tricarboxylic Acid Cycle Intermediates* , 2007, Journal of Biological Chemistry.

[50]  J. Whitfield,et al.  Tumor microenvironment: becoming sick of Myc , 2011, Cellular and Molecular Life Sciences.

[51]  J. Larrick,et al.  Partial reversal of skeletal muscle aging by restoration of normal NAD⁺ levels. , 2014, Rejuvenation research.

[52]  Danica Chen,et al.  The sirtuins, oxidative stress and aging: an emerging link , 2013, Aging.

[53]  David G. Watson,et al.  Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. , 2005, Cancer cell.

[54]  G. Semenza,et al.  HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. , 2013, The Journal of clinical investigation.

[55]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[56]  Yu Wang,et al.  SIRT1 and AMPK in regulating mammalian senescence: A critical review and a working model , 2011, FEBS letters.

[57]  I. Scott,et al.  The role of sirtuins in modulating redox stressors. , 2012, Free radical biology & medicine.

[58]  G. Semenza,et al.  Induction of HIF‐1α expression by intermittent hypoxia: Involvement of NADPH oxidase, Ca2+ signaling, prolyl hydroxylases, and mTOR , 2008, Journal of cellular physiology.

[59]  P. Puigserver,et al.  AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity , 2009, Nature.

[60]  A. Ptitsyn,et al.  Unsupervised clustering of gene expression data points at hypoxia as possible trigger for metabolic syndrome , 2006, BMC Genomics.

[61]  M. Blagosklonny.  MTOR-driven quasi-programmed aging as a disposable soma theory , 2013, Cell cycle.

[62]  E. Bernhard,et al.  Akt1 Activation Can Augment Hypoxia-Inducible Factor-1α Expression by Increasing Protein Translation through a Mammalian Target of Rapamycin–Independent Pathway , 2006, Molecular Cancer Research.

[63]  Sarah J. Kurley,et al.  MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. , 2014, The Journal of clinical investigation.

[64]  P. Bénit,et al.  The Warburg Effect Is Genetically Determined in Inherited Pheochromocytomas , 2009, PloS one.

[65]  J. Nyengaard,et al.  Interactions between hyperglycemia and hypoxia: implications for diabetic retinopathy. , 2004, Diabetes.

[66]  Wilhelm Krek,et al.  Dietary obesity-associated Hif1α activation in adipocytes restricts fatty acid oxidation and energy expenditure via suppression of the Sirt2-NAD+ system. , 2012, Genes & development.

[67]  Stephen Lee,et al.  Subcellular dynamics of the VHL tumor suppressor: on the move for HIF degradation. , 2009, Future oncology.

[68]  D. Hanahan,et al.  Endogenous Myc maintains the tumor microenvironment. , 2011, Genes & development.

[69]  D. Sinclair,et al.  Manipulation of a Nuclear NAD+ Salvage Pathway Delays Aging without Altering Steady-state NAD+ Levels* , 2002, The Journal of Biological Chemistry.

[70]  J. Wood,et al.  Sirtuin activators mimic caloric restriction and delay ageing in metazoans , 2004, Nature.

[71]  P. Rustin,et al.  Tricarboxylic acid cycle dysfunction as a cause of human diseases and tumor formation. , 2006, American journal of physiology. Cell physiology.

[72]  G. Evan,et al.  The ups and downs of Myc biology. , 2010, Current opinion in genetics & development.

[73]  M. Blagosklonny,et al.  Hypoxia and gerosuppression: The mTOR saga continues , 2012, Cell cycle.

[74]  M. Blagosklonny.  Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging , 2012, Aging.

[75]  Sandro Santagata,et al.  A HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas , 2005, PLoS genetics.

[76]  J. Lozano-Sánchez,et al.  Xenohormetic and anti-aging activity of secoiridoid polyphenols present in extra virgin olive oil , 2013, Cell cycle.

[77]  S. Chiou,et al.  Transplantation of induced pluripotent stem cells without C-Myc attenuates retinal ischemia and reperfusion injury in rats. , 2013, Experimental eye research.

[78]  P. Ward,et al.  Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. , 2012, Cancer cell.

[79]  Harman Ece,et al.  Use of oral antidiabetic drugs (metformin and pioglitazone) in diabetic patients with breast cancer: how does it effect serum Hif-1 alpha and 8Ohdg levels? , 2012, Asian Pacific journal of cancer prevention : APJCP.

[80]  N. Larsson.  Somatic mitochondrial DNA mutations in mammalian aging. , 2010, Annual review of biochemistry.

[81]  M. Blagosklonny.  Molecular damage in cancer: an argument for mTOR-driven aging , 2011, Aging.

[82]  E. Van Obberghen,et al.  AMPK activation inhibits the expression of HIF-1alpha induced by insulin and IGF-1. , 2006, Biochemical and biophysical research communications.

[83]  Dudley Lamming,et al.  Nutrient-Sensitive Mitochondrial NAD+ Levels Dictate Cell Survival , 2007, Cell.

[84]  R. Deberardinis,et al.  Silencing a Metabolic Oncogene , 2013, Science.

[85]  Tomoyoshi Soga,et al.  Oncometabolites: linking altered metabolism with cancer. , 2013, The Journal of clinical investigation.

[86]  R. de Cabo,et al.  SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. , 2012, Cell metabolism.

[87]  M. Blagosklonny.  Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions , 2012, Oncotarget.

[88]  M. Hiraoka,et al.  The Akt/mTOR Pathway Assures the Synthesis of HIF-1α Protein in a Glucose- and Reoxygenation-dependent Manner in Irradiated Tumors* , 2009, Journal of Biological Chemistry.

[89]  C. Brennan,et al.  Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine , 2013, Oncotarget.

[90]  R. Mostoslavsky,et al.  Fine tuning our cellular factories: sirtuins in mitochondrial biology. , 2011, Cell metabolism.

[91]  Eyal Gottlieb,et al.  Inborn and acquired metabolic defects in cancer , 2011, Journal of Molecular Medicine.

[92]  Laurence Amar,et al.  SDH mutations establish a hypermethylator phenotype in paraganglioma. , 2013, Cancer cell.

[93]  K. Sharp,et al.  Identification of additional IDH mutations associated with oncometabolite R(−)-2-hydroxyglutarate production , 2012, Oncogene.

[94]  Timothy J. Nelson,et al.  Nuclear Reprogramming with c-Myc Potentiates Glycolytic Capacity of Derived Induced Pluripotent Stem Cells , 2013, Journal of Cardiovascular Translational Research.

[95]  Omar Abdel-Wahab,et al.  The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. , 2010, Cancer cell.

[96]  M. Blagosklonny.  Rapamycin extends life- and health span because it slows aging , 2013, Aging.

[97]  M. Blagosklonny.  Big mice die young but large animals live longer , 2013, Aging.

[98]  J. Nyengaard,et al.  Hyperglycemic Pseudohypoxia and Diabetic Complications , 1993, Diabetes.

[99]  J. Kieswich,et al.  Metformin opposes impaired AMPK and SIRT1 function and deleterious changes in core clock protein expression in white adipose tissue of genetically‐obese db/db mice , 2011, Diabetes, obesity & metabolism.

[100]  R. Deberardinis,et al.  The proto-oncometabolite fumarate binds glutathione to amplify ROS-dependent signaling. , 2013, Molecular cell.

[101]  G. Evan,et al.  Reversible kinetic analysis of Myc targets in vivo provides novel insights into Myc-mediated tumorigenesis. , 2006, Cancer research.

[102]  G. Shadel,et al.  Revisiting the TCA cycle: signaling to tumor formation. , 2011, Trends in molecular medicine.

[103]  Benjamin L. Ebert,et al.  (R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible , 2013, Science.

[104]  M. Eilers,et al.  Facilitating replication under stress: an oncogenic function of MYC? , 2009, Nature Reviews Cancer.

[105]  G. Evan,et al.  The Action Mechanism of the Myc Inhibitor Termed Omomyc May Give Clues on How to Target Myc for Cancer Therapy , 2011, PloS one.

[106]  G. Evan,et al.  Omomyc expression in skin prevents Myc-induced papillomatosis , 2004, Cell Death and Differentiation.

[107]  De-Pei Liu,et al.  Sirt1 deacetylates c-Myc and promotes c-Myc/Max association. , 2011, The international journal of biochemistry & cell biology.

[108]  E. Van Obberghen,et al.  Regulation of hypoxia-inducible factor (HIF)-1 activity and expression of HIF hydroxylases in response to insulin-like growth factor I. , 2005, Molecular endocrinology.

[109]  R. Klose,et al.  The oncometabolite 2‐hydroxyglutarate inhibits histone lysine demethylases , 2011, EMBO reports.

[110]  M. Blagosklonny,et al.  Mechanistic or mammalian target of rapamycin (mTOR) may determine robustness in young male mice at the cost of accelerated aging , 2012, Aging.

[111]  Andrew L. Kung,et al.  A HIF1-alpha Regulatory Loop Links Hypoxiaand Mitochondrial Signals in Pheochromocytomas , 2005 .

[112]  D. Felsher,et al.  MYC as a regulator of ribosome biogenesis and protein synthesis , 2010, Nature Reviews Cancer.

[113]  T. Mak,et al.  Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. , 2013, Cancer discovery.

[114]  M. Blagosklonny.  Prospective treatment of age-related diseases by slowing down aging. , 2012, The American journal of pathology.

[115]  P. M. Dahia,et al.  Transcription Association of VHL and SDH Mutations Link Hypoxia and Oxidoreductase Signals in Pheochromocytomas , 2006, Annals of the New York Academy of Sciences.

[116]  A. Terzic,et al.  Metabolic plasticity in stem cell homeostasis and differentiation. , 2012, Cell stem cell.

[117]  Russell G. Jones,et al.  Tumor suppressors and cell metabolism: a recipe for cancer growth. , 2009, Genes & development.

[118]  G. Evan,et al.  Myc-Is this the oncogene from Hell? , 2002, Cancer cell.

[119]  Tomoyoshi Soga,et al.  The emerging role of fumarate as an oncometabolite , 2012, Front. Oncol..

[120]  G. Riggins,et al.  Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. , 2010, Cancer research.

[121]  E. Gottlieb,et al.  Cell-Permeating α-Ketoglutarate Derivatives Alleviate Pseudohypoxia in Succinate Dehydrogenase-Deficient Cells , 2007, Molecular and Cellular Biology.

[122]  Guido Kroemer,et al.  Tumor cell metabolism: cancer's Achilles' heel. , 2008, Cancer cell.

[123]  Ying He,et al.  Sirtuin 1–Mediated Cellular Metabolic Memory of High Glucose Via the LKB1/AMPK/ROS Pathway and Therapeutic Effects of Metformin , 2011, Diabetes.

[124]  M. Blagosklonny.  Hormesis does not make sense except in the light of TOR-driven aging , 2011, Aging.

[125]  Jesse M. Platt,et al.  Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability , 2011, Proceedings of the National Academy of Sciences.

[126]  B. Lakshmi,et al.  Rapid non-genomic signalling by 17β-oestradiol through c-Src involves mTOR-dependent expression of HIF-1α in breast cancer cells , 2011, British Journal of Cancer.